TrialHaematologica2015

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.

Gabriele Gugliotta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.